Drug intelligence / Profile preview

NST-0036

Development stage: Preclinical
Lead developer: Novasenta
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Parenteral (likely Intravenous Or Subcutaneous; Specific Route Not Disclosed)

Overview

NST-0036 is a monoclonal antibody developed by Novasenta for the treatment of cancer. It acts as an immunomodulator targeting CD161, an immune cell surface receptor implicated in tumor immune evasion. The drug is designed to modulate the activity of immune cells within the tumor microenvironment, potentially enhancing anti-tumor immunity. As of April 2025, its highest development status is in the discovery or early research phase and it has not yet entered clinical trials[1][2].

Targets

KLRB1 (C-type lectin-like receptor CD161)

Beyond the preview

Go deeper on NST-0036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NST-0036.

Explore the full profile